Sign In
Buy GRTX
$0.100
-0.0010 (-0.99%)
At Close: Jun 03, 2026
Event to be webcast on Thursday, September 23 at 11:00 a.m. ET
Galera Announces Final Results from Pancreatic Cancer Trial Showing Improvements on all Efficacy Parameters
07:00am, Wednesday, 08'th Sep 2021
Improvements observed in overall survival, progression-free survival, local tumor control, time to metastases, and tumor response rate
Galera to Present at Three Upcoming Investor Conferences in September
07:00am, Tuesday, 07'th Sep 2021
MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro
Galera Announces Completion of Enrollment in Pivotal 455-Patient Phase 3 Trial of Avasopasem for Severe Oral Mucositis
07:00am, Monday, 28'th Jun 2021
Topline data expected in the second half of 2021
Galera Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer
07:00am, Monday, 17'th May 2021
Initiation builds on positive overall survival and tumor control data from Phase 1/2 trial
Galera to Participate in the BofA Securities 2021 Virtual Healthcare Conference
07:00am, Wednesday, 05'th May 2021
MALVERN, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propr
GRTX Stock: From $6.61 To Over $8.80 Pre-Market Explanation
07:04am, Thursday, 29'th Apr 2021
The stock price of Galera Therapeutics Inc (NASDAQ: GRTX) increased over 34% as it went from a previous close of $6.61 to over $8.80 pre-market. This is why it happened.
Galera Announces Updated Data from its Randomized, Multicenter, Placebo-Controlled Trial in Patients with Pancreatic Cancer
04:01pm, Wednesday, 28'th Apr 2021
Near double the median overall survival observed in patients receiving Galera's dismutase mimetic + SBRT versus placebo + SBRT, showing strong therapeutic potential
Galera Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference
08:00am, Wednesday, 10'th Mar 2021
MALVERN, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro
Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
08:00am, Friday, 20'th Nov 2020
MALVERN, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, prop
Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates
07:00am, Tuesday, 10'th Nov 2020
Presented Promising Interim Data from Placebo-controlled P ilot Dismutase Mimetic SBRT Combination Trial for P ancreatic C ancer
Galera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
08:00am, Tuesday, 03'rd Nov 2020
MALVERN, Pa., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, prop
Initial results from pilot Phase 1/2 clinical trial in patients with locally advanced pancreatic cancer presented during virtual ASTRO Annual Meeting
Galera Therapeutics: Reasonable Valuation With Fast Track And Breakthrough Designation
10:04am, Monday, 07'th Sep 2020
Galera Therapeutics is a promising company backed by prestigious venture firms. GC4419's success let to fast track and breakthrough designation by the FDA.
Galera Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
11:00am, Monday, 10'th Aug 2020
Completed Enrollment of Randomized, Blinded, Placebo-controlled Trial of GC4419 in Combination with Radiotherapy in Locally Advanced Pancreatic Cancer; Topline Data Readout Expected in 2H20 Phase 3 R
